STOK vs ANNX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
STOK Captures Institutional Edge (2โ1 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Stoke Therapeutics, Inc. Common Stock (STOK) driven by superior Growth & Margin, Options & Structure while ANNX counters with relative strength in Momentum & Technical. Fundamentally, STOK trades at N/M Forward P/E with -913.2% operating margin (+5.9% YoY revenue) versus ANNX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, STOK sits in SURGE (8th %ile IV; Dealer Gamma Walls on Pro) against ANNX sits in BREAKDOWN (40th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | STOK | ANNX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.7B | $757.3M | Larger Scale | STOK |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +5.9% | +0.0% | Higher Growth | STOK |
| Operating Margin (TTM) Profitability | -913.2% | 0.0% | Higher Margin | ANNX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -73.6% | -130.8% | Higher ROE | STOK |
| 52-Week Range Position Momentum | 25% ($22โ$40) | 22% ($3โ$7) | Stronger Trend | STOK |
| Beta / 30D Volatility Risk Regime | 0.99ฮฒ ยท 47% Vol | 1.68ฮฒ ยท 62% Vol | Lower Realized Risk | STOK |
| Unified Institutional Score Composite Signal | 56.7 / 100 (HOLD) | 44.6 / 100 (HOLD) | Higher Composite | STOK |